中国医药
中國醫藥
중국의약
CHINA MEDICINE
2009年
11期
833-835
,共3页
潘海燕%汪得喜%卢小卓%曾瑜%钟海波%邓思健%邹石海%伍晓峰
潘海燕%汪得喜%盧小卓%曾瑜%鐘海波%鄧思健%鄒石海%伍曉峰
반해연%왕득희%로소탁%증유%종해파%산사건%추석해%오효봉
慢性阻塞性肺疾病%瘦素%瘦素受体%汉防己甲素
慢性阻塞性肺疾病%瘦素%瘦素受體%漢防己甲素
만성조새성폐질병%수소%수소수체%한방기갑소
Chronic obstructive pulmonary diseases%Leptin%Leptin-receptor%Tetrandrine
目的 探讨汉防己甲素对慢性阻塞性肺疾病(COPD)急性加重期患者局部瘦素及瘦紊受体表达的影响.方法 按照入院顺序编号将80例患者分为2组:汉防己甲素治疗组与经典治疗组各加例.采用酶链免疫方法测定治疗前后血清及诱导痰瘦素(Leptin)、可溶性瘦素受体(sLR)、白细胞介素8(IL-8),并同时测定血清C反应蛋白(CRP),肺功能、血气分析等,对上述指标进行对比分析.结果 2组治疗前比较:Leptin、sLR、IL-8及血清CRP差异无统计学意义,治疗后汉防已甲素治疗组Leptin、sLR、IL-8及血清CRP比经典治疗组下降明显,差异有统计学意义[(4.16±0.22,24.45±0.73,25.35±0.35,16.09±0.86)vs(7.76±0.19,28.97±10.11,19.99±0.97),P<0.05或P<0.01],诱导痰Leptin与血清Leptin呈正相关(P<0.05),而与血清sLR、IL-8、CRP无统计学意义(P>0.05).结论 汉防己甲素能改善急性加重COPD患者的全身及气道局部炎症状态,同时下调瘦素、瘦素受体、IL-8、CRP的水平.
目的 探討漢防己甲素對慢性阻塞性肺疾病(COPD)急性加重期患者跼部瘦素及瘦紊受體錶達的影響.方法 按照入院順序編號將80例患者分為2組:漢防己甲素治療組與經典治療組各加例.採用酶鏈免疫方法測定治療前後血清及誘導痰瘦素(Leptin)、可溶性瘦素受體(sLR)、白細胞介素8(IL-8),併同時測定血清C反應蛋白(CRP),肺功能、血氣分析等,對上述指標進行對比分析.結果 2組治療前比較:Leptin、sLR、IL-8及血清CRP差異無統計學意義,治療後漢防已甲素治療組Leptin、sLR、IL-8及血清CRP比經典治療組下降明顯,差異有統計學意義[(4.16±0.22,24.45±0.73,25.35±0.35,16.09±0.86)vs(7.76±0.19,28.97±10.11,19.99±0.97),P<0.05或P<0.01],誘導痰Leptin與血清Leptin呈正相關(P<0.05),而與血清sLR、IL-8、CRP無統計學意義(P>0.05).結論 漢防己甲素能改善急性加重COPD患者的全身及氣道跼部炎癥狀態,同時下調瘦素、瘦素受體、IL-8、CRP的水平.
목적 탐토한방기갑소대만성조새성폐질병(COPD)급성가중기환자국부수소급수문수체표체적영향.방법 안조입원순서편호장80례환자분위2조:한방기갑소치료조여경전치료조각가례.채용매련면역방법측정치료전후혈청급유도담수소(Leptin)、가용성수소수체(sLR)、백세포개소8(IL-8),병동시측정혈청C반응단백(CRP),폐공능、혈기분석등,대상술지표진행대비분석.결과 2조치료전비교:Leptin、sLR、IL-8급혈청CRP차이무통계학의의,치료후한방이갑소치료조Leptin、sLR、IL-8급혈청CRP비경전치료조하강명현,차이유통계학의의[(4.16±0.22,24.45±0.73,25.35±0.35,16.09±0.86)vs(7.76±0.19,28.97±10.11,19.99±0.97),P<0.05혹P<0.01],유도담Leptin여혈청Leptin정정상관(P<0.05),이여혈청sLR、IL-8、CRP무통계학의의(P>0.05).결론 한방기갑소능개선급성가중COPD환자적전신급기도국부염증상태,동시하조수소、수소수체、IL-8、CRP적수평.
Objective To investigate the effect and role of the tetrandrine on the expression of leptin and leptin receptor of patient with COPD in systemic and local on acute exacerbation phase. Methods Eighty patients with COPD were randomly divided into two study groups: tetrandrine treating group(first group n =40) and routine treating group(second group n =40). The expression of leptin and the leptin receptor, IL-8 in serum and in induced sputum were measured by enzyme linked immunosorbent assay (ELISA), CRP was measured by turbidimetry. Blood gas analysis, pulmonary function testing was done routinely. Result There were no significant differences between two groups in the leptin,leptin receptor, IL-8, CRP in serum and the leptin,leptin receptor, IL-8 in the induced sputum before the treatment. Those indexes were significantly lower in the first group than in the the second group after treatment (P <0.05 and P <0.01). Significant correlations were found among the leptin in induced sputum and leptin in serum and leptin receptor, IL-8 in induced sputum. Leptin in induced sputum did not correlate with leptin receptor and IL-8 and CRP in serum. Conclusioions The leptin is involved in the system and airway flamma-tory prespose of the acute exacerbation phase with COPD. Tetrandrine can improve the systemic and local inflamma-tion and down-regulate the expression of leptin, leptin receptor and IL-8, CRP on the patient in acute exacerbation phase with COPD.